Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesTissue Repair Ltd

Tissue Repair Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.11 AUD -0.02 ( 15.38%)
Last update at 2026-11-12T01:03:00Z
VOLUME
2908
Market Cap
6.92M

Momentum Score

…

Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures. Tissue Repair Ltd was incorporated in 2012 and is based in Chatswood, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.11
Low
0.11
High
52 Week Price Range
0.06
Low
0.48
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Tissue Repair Ltd is an Australian life sciences company focused on developing and commercializing products for wound repair and skin health. Long-term growth drivers include aging populations and rising chronic-wound prevalence, plus potential clinical and regulatory milestones and commercialization or partnership outcomes that could support revenue expansion; investors may find the company attractive for its focused pipeline and niche market exposure. The most important investment risks are binary clinical and regulatory outcomes, limited operating history and small-cap financing and execution risk that could materially affect prospects.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.13
Dividend Yield
-
Revenue TTM
2.99M
Revenue Per Share
0.05
Gross Profit TTM
2.77M
Debt / Equity
-
ROE
-47.27%
Net Debt
-4.77M
ROCE
-90.81%
Diluted EPS TTM
-0.09

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -7.79M -4.24M -4.14M -4.17M -6.84M
Net income -5.36M -4.24M -4.14M -4.17M -6.84M
Selling general administrative - 1.51M 2.39M 1.18M 1.87M
Selling and marketing expenses - 0.88M 0.27M - -
Gross profit -1.80M 2.63M 0.15M 0.00M -
Reconciled depreciation - - 0.00M 0.00M 0.00M
Ebit - -4.83M -6.52M -4.77M -6.84M
Ebitda -7.98M -4.72M -6.51M -5.74M -6.84M
Depreciation and amortization - 0.10M 0.00M - 0.00M
Operating income -7.98M -4.72M -6.52M -4.77M -6.84M
Other operating expenses 8.54M 7.35M 6.67M - 5.45M
Interest expense - - - - 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.20M 0.74M 0.60M 0.04M
Net interest income - - 0.74M 0.43M 0.04M
Income tax expense -2.43M - -1.64M - -1.43M
Total revenue 0.56M 2.63M 0.15M 0.00M 0.00M
Total operating expenses 6.17M 7.35M 6.67M - 5.45M
Cost of revenue 2.36M - 0.00M - -
Total other income expense net 0.18M 0.48M 0.74M 1.14M -1.43M
Net income from continuing ops - - -4.14M -4.17M -6.84M
Net income applicable to common shares - -4.24M -4.14M -4.17M -6.84M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 10.34M 14.57M 19.39M 22.38M 25.90M
Other current assets 0.23M 0.20M 0.20M 0.02M 0.06M
Total liab 1.57M 0.66M 1.35M 0.50M 0.56M
Total stockholder equity 8.77M 13.91M 18.04M 21.88M 25.34M
Other current liab 0.58M 0.38M 0.70M 0.03M 0.36M
Common stock - 35.04M 35.04M 35.04M 35.04M
Capital stock - - - 35.04M 35.04M
Retained earnings -28.54M -23.18M -18.94M -14.80M -10.63M
Other liab - - - 0.01M 0.00M
Cash 4.77M 12.32M 16.44M 21.40M 25.46M
Total current liabilities 1.56M 0.64M 1.34M 0.49M 0.56M
Net debt -4.77M -12.32M -16.44M - -25.46M
Short term debt - - - 0.00M 0.00M
Other stockholder equity 37.32M - - 1.65M 0.93M
Property plant equipment - - - 0.00M 0.00M
Total current assets 9.93M 14.25M 19.39M 22.38M 25.90M
Net tangible assets - - - 21.88M 25.34M
Net receivables 4.20M 1.74M 2.53M 0.83M 0.05M
Long term debt - - - - 0.00M
Inventory 0.74M 0.00M 0.21M 0.02M -
Accounts payable 0.98M 0.26M 0.64M 0.08M 0.20M
Accumulated other comprehensive income - 2.05M 1.94M - 0.93M
Non currrent assets other 0.27M - 0.00M - -
Non current assets total 0.41M 0.32M 0.00M 0.00M 0.00M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -0.00M -0.00M -0.00M
Change to liabilities - - - -0.10M 0.01M
Total cashflows from investing activities -0.04M -0.42M -0.00M -0.00M -0.00M
Total cash from financing activities - 0.00M 0.00M 0.00M 21.36M
Change to operating activities - - - -0.03M -0.08M
Net income -5.36M -4.24M -4.14M -4.17M -6.84M
Change in cash -7.55M -4.12M -4.96M -4.06M 17.69M
Begin period cash flow 12.32M 16.44M 21.40M 25.46M 7.76M
End period cash flow 4.77M 12.32M 16.44M 21.40M 25.46M
Total cash from operating activities -7.50M -3.70M -4.95M -4.26M -3.97M
Issuance of capital stock - - - - 22.00M
Depreciation 0.22M 0.10M 0.00M 0.00M 0.00M
Other cashflows from investing activities - - - - 0.00M
Change to inventory -1.01M 0.21M -0.19M -0.02M -0.02M
Change to account receivables -2.48M 0.74M -1.70M -0.45M 0.01M
Sale purchase of stock - - - 0.00M -0.64M
Other cashflows from financing activities - 0.00M -0.00M 0.00M -0.00M
Change to netincome - - - 0.52M 2.93M
Capital expenditures 0.04M 0.42M 0.00M 0.00M 0.00M
Change in working capital -2.59M 0.70M -1.11M 0.42M 0.01M
Stock based compensation - 0.11M 0.30M - -
Other non cash items 0.23M -0.38M 0.30M - -
Free cash flow -7.55M -4.12M -4.95M -4.26M -0.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TRP
Tissue Repair Ltd		 -0.02
15.38%		 0.11 - - 2.32 0.70 2.42 1.96
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Tissue Repair Ltd

Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures. Tissue Repair Ltd was incorporated in 2012 and is based in Chatswood, Australia.

Tower A, The Zenith, Chatswood, NSW, Australia, 2067

61 4 2798 5805

https://tissuerepair.com.au

Name Title Year Born
Mr. Tony Charara Co-Founder & Exec. Director NA
Mr. Cameron Jones C.A. Chief Financial Officer NA
Dr. Darryl Reed Chief Operating Officer NA
Mr. Michael Austin Company Sec. NA
Ms. Priyamvada Sanjay Rasal Company Secretary NA
Mr. Tony Charara Co-Founder & Executive Director NA
Mr. Tony Charara Co-Founder & Executive Director NA
Mr. Tony Charara Co-Founder & Executive Director NA
Ms. Priyamvada Sanjay Rasal Company Secretary NA
Mr. Tony Charara Co-Founder & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…